AU Patent

AU2021201228B2 — Improved lipid formulation

Assigned to Arbutus Biopharma Corp · Expires 2022-07-07 · 4y expired

What this patent protects

IH:\grs\Interwovn\NRPortbl\DCC\GRS\ 4056299 _.docx-20/04/2017 IMPROVED LIPID FORMULATION Abstract The invention features a cationic lipid of formula (I), an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed a…

USPTO Abstract

IH:\grs\Interwovn\NRPortbl\DCC\GRS\ 4056299 _.docx-20/04/2017 IMPROVED LIPID FORMULATION Abstract The invention features a cationic lipid of formula (I), an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021201228B2
Jurisdiction
AU
Classification
—
Expires
2022-07-07
Drug substance claim
No
Drug product claim
No
Assignee
Arbutus Biopharma Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.